Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis

Nektar Therapeutics NKTR:

• REZOLVE-AD PHASE 2B STUDY OF REZPEGALDESLEUKIN MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

• NEKTAR THERAPEUTICS - REZOLVE-AD PHASE 2B STUDY MEETS PRIMARY AND KEY SECONDARY ENDPOINTS

• NEKTAR THERAPEUTICS - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 16

• NEKTAR THERAPEUTICS - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED RESULTS

• NEKTAR THERAPEUTICS: DATA EXPECTED IN Q1 2026 FROM TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS IN LONG-TERM MAINTENANCE PART OF REZOLVE-AD STUDY

• NEKTAR THERAPEUTICS -TOP-LINE PHASE 2B DATA FOR REZPEGALDESLEUKIN IN ALOPECIA AREATA EXPECTED IN Q4 2025